Bench
Library

KLOW blend

Blends

Also known as KLOW 80, GHK-Cu + BPC-157 + TB-500 + KPV

A four-peptide repair blend, sold as 80 mg in a 5:1:1:1 ratio.

Read this first
The fixed 5:1:1:1 ratio means you cannot titrate the components independently. A dose that delivers a conventional 250 to 500 mcg of BPC-157 simultaneously delivers 1.25 to 2.5 mg of GHK-Cu, which is at or above the whole community range for GHK-Cu on its own. Dosing this blend to hit a BPC-157 target means dosing copper hard.

How it works

Combines a copper-carrying skin peptide, two soft-tissue repair peptides and an anti-inflammatory tripeptide. Each component has its own preclinical rationale; the combination has never been studied.

Subcutaneous

In the body

No plasma curve is shown for this compound.

Not meaningful for a blend whose components have half-lives ranging from minutes to unknown. Track the components separately if you want a curve.

Doses

1 mg, 3 mgonce dailyCommunity practice

Total blend mass per dose, rotating injection sites. Every figure here comes from vendor and enthusiast sites.

What is in it

What a dose delivers

mcg
  • 1.25 mgGHK-Cu63% of blendin usual rangeusually 500 mcg, 10 mg per dose, applied twice dailyno published half-life
  • 250 mcgBPC-15713% of blendin usual rangeusually 250 mcg, 500 mcg per dose, once or twice dailyhalf-life 25 minutes
  • 250 mcgTB-50013% of blendbelow usualusually 2 mg, 2.5 mg per dose, twice weekly loading, then weeklyno published half-life
  • 250 mcgKPV13% of blendin usual rangeusually 250 mcg, 500 mcg per dose, once or twice dailyno published half-life

TB-500 is below the usual standalone amount at this dose.

Vial sizes

80 mg

Commonly treated as good for 21 days refrigerated once reconstituted.

Side effects

  • No safety data on the combination exists.
  • Copper load from the GHK-Cu component is the main practical concern.

Cautions

  • Everything that applies to each component, in particular the copper cautions on GHK-Cu and the cancer cautions on BPC-157 and TB-500.

Status

Not approved. No published trial has evaluated this four-peptide combination.

Sources

Reference information for personal record-keeping. Not medical advice, and not a recommendation to use any of these compounds.